

2012 Annual Conference Learning Objectives

ACPE #0129-0000-12-028-L01-P

Borderline Personality: Into the Chaos

Randy A. Sansone, M.D., Professor, Psychiatry & Internal Medicine, Wright State University School of Medicine

At the completion of this activity, the participant will be able to:

1. Describe the general relationship between substance misuse and psychiatric pathology;
2. Define Borderline Personality Disorder (BPD) according to three basic features;
3. Describe the prevalence of BPD in the general population;
4. Describe the five Gunderson criteria for BPD; and
5. Describe the format of the Self-Harm Inventory.

ACPE #0129-0000-12-029-L01-P

PRO: Addiction Help for Pharmacists

Nick Kallis, R.Ph. and Jarrod Grossman, PharmD, R.Ph., Pharmacists Rehabilitation Organization

At the completion of this activity, the participant will be able to:

1. List risk factors for alcohol or other chemical addiction;
2. Recognize the signs and symptoms of an individual experiencing addiction, and warning signs of impairment in health care professionals;
3. Identify prescription, over-the counter and herbal medications that may be safely used, and those which should be avoided, in recovering addicts;
4. Recommend recovery resources for pharmacists or pharmacy interns experiencing addiction.

ACPE #0129-0000-12-030-L01-P

Hyperlipidemia Consensus Guidelines and Niacin Controversy

Ryan Schneider, PharmD, PhD, Assistant Professor of Pharmaceutical Sciences, UF College of Pharmacy

At the completion of this activity, the participant will be able to:

1. Explain the current consensus guidelines for managing patients with hyperlipidemia and be able to assign treatment goals given a patient case;
2. Compare and contrast the mechanisms of action, lipid lowering effects and adverse effects of various antihyperlipidemic drugs and determine the appropriate use of each;
3. List recent changes to the simvastatin label and restrictions on the use of high-dose simvastatin;
4. Summarize the AIM-HIGH study results involving the combination of a statin and high dose, extended-release niacin and discuss the potential clinical implications these results may have on the future of lipid-lowering therapy; and
5. Assess patient cases and determine the most appropriate recommendations for antihyperlipidemic therapy.

ACPE #0129-0000-12-032-L01-P

Antithrombotic Therapy: It's Not Just Aspirin, Warfarin, and Heparin Anymore!

Vincent F. Mauro, R.Ph., PharmD, FCCP

Professor of Clinical Pharmacy, University of Toledo College of Pharmacy and Pharmaceutical Sciences

At the completion of this activity, the participant will be able to:

1. Distinguish the differences between antiplatelet and anticoagulant therapy;
2. Describe the pharmacological activity of the new antithrombotic agents; and
3. Summarize significant or unique clinical features of the new antithrombotic agents.

ACPE #0129-0000-12-033-L01-P

2012 OTC and Self-Care Challenge

Kristin Casper, R.Ph., PharmD, Associate Professor of Clinical Pharmacy, The Ohio State University College of Pharmacy; and Andrea Wall, R.Ph., Assistant Dean for Student Affairs, University of Cincinnati College of Pharmacy

At the completion of this activity, the participant will be able to:

1. Discuss current topics related to nonprescription medications;
2. Describe appropriate nonprescription treatment options for common self-care conditions; and
3. Identify the rationale for the selection of a particular product for a described self-care condition.

ACPE #0129-0000-12-034-L04-P

PBMs: Who's on First

*Zachary French, Vice President PBM Transparency Initiatives
National Community Pharmacists Association*

At the completion of this activity, the participant will be able to:

1. Discuss the perspective of the plan manager on mail order prescription plans;
2. Evaluate the logic behind differential MAC tables;
3. Identify decision making points for the plan in selecting a PBM;
4. Outline tools that can be used with NCPA or state association on anti-mail strategies for his/her community pharmacy; and
5. Describe how to put together information to present to local employers to make the case for his/her community pharmacy business.

ACPE #0129-0000-12-035-L04-P

Essence of Leadership

Milap C. Nahata, PharmD, MS

Director, Institute of Therapeutic Innovations and Outcomes, OSU College of Pharmacy

At the completion of this activity, the participant will be able to:

1. Define the meaning of leadership;
2. Differentiate between leadership and management;
3. Recognize attributes of successful leaders; and
4. Identify strategies to enhance leadership skills.

ACPE #0129-0000-12-036-L04-P

Pharmacists Affecting Care Transitions: Building the Bridge Together

Joseph Dula, R.Ph., PharmD, Regional Director of Clinical Services, Pharmacy Systems, Inc. and Larry Schieber, R.Ph., Owner and Operator, Schieber Family Pharmacy, Circleville

At the completion of this activity, the participant will be able to:

1. Explain the value and impact of pharmacist involvement on cost of treatment and patient safety to hospital administration, physicians, and nurses;
2. Describe ways to partner with community (retail/outpatient) pharmacies to foster continuity of care and facilitate consistent application of medication therapy management activities; and
3. Identify the medication related problem avoidance and other documented outcomes that a pharmacist-based transition of care service can deliver to a community hospital system.

ACPE #0129-0000-12-037-L01-P

Aspects and Management of Pain in the Hospice Setting

Maureen L. Jones, R.Ph., PharmD, Clinical Pharmacist, HospiScript, a Catalyst Rx Company

At the completion of this activity, the participant will be able to:

1. Identify the common types of pain in terminal diseases and their impact on medication selection;
2. Select appropriate medication regimens for the treatment of pain based on the source of the pain, therapeutic goal, side effects encountered and concomitant therapies;
3. Explain the role of hospice interdisciplinary teams in the effective management of pain;
4. Describe the value of comprehensive medication reviews in the hospice patient; and
5. State the laws regulating the dispensing of CII narcotics in the hospice setting.

ACPE #0129-0000-12-038-L04-P

Ohio Research Forum 2012

Moderator: Curtis Black, R.Ph., PhD, Distinguished University Professor Emeritus

College of Pharmacy & Pharmaceutical Sciences, The University of Toledo

At the completion of this activity, the participant will be able to:

1. Identify research projects being conducted by pharmacists, pharmacy students and faculty at the colleges of pharmacy in Ohio;
2. Explain the results of these research projects in terms of the effects of drugs;
3. Describe the impact these research projects may have on medication therapy management and the contemporary practice of pharmacy; and
4. Explain the pharmacoeconomic issues associated with this research.

ACPE #0129-0000-12-039-L04-P

Optimizing the Role of Pharmacists: the APhA Foundation's Project IMPACT Diabetes Model and Beyond

Mindy D. Smith, BSPHarm, R.Ph., Executive Director and Benjamin M. Bluml, R.Ph., VP Research, American Pharmacists Association Foundation

At the completion of this activity, the participant will be able to:

1. Define the term "align incentives" including the three groups that this applies to;
2. Identify the two primary benefits associated with pharmacist-provided care that have been demonstrated through APhA Foundation research projects (Improved clinical outcomes, controlled costs);
3. List potential barriers to implementing this type of care (legislation, payers, patient expectations); and
4. Name types of environments in which the pharmacist care model has been or is being tested; examples include provider settings, payers, and populations (self-insured employers, disproportionate share, FQHC, independent, chain, ambulatory).

ACPE #0129-0000-12-040-L04-P

Pharmacists' Critical Role in Patient Care: Federal Perspective

John Michael O'Brien, PharmD, MPH, National Field Director, CMS Innovation Center

At the completion of this activity, the participant will be able to:

1. Describe the pharmacist's critical role in improving the patient transition from home to hospital, and hospital to extended care or home;
2. Discuss the errors and omissions in care which are being corrected by pharmacists; and
3. Recognize new areas for service and reimbursement for pharmacists.

ACPE #0129-0000-12-041-L01-P

Immunization Update

Debra L. Parker, R.Ph., PharmD, Chair & Assistant Professor, UF College of Pharmacy; and Darrin Rosebrook, Impact SIIS Trainer

At the completion of this activity, the participant will be able to:

1. Determine patient-specific immunization schedules for those vaccines approved for pharmacist-delivery in Ohio;
2. Apply current Advisory Committee on Immunization Practices recommendations to clinical practice;
3. Identify sources for accurate and accessible education regarding disease prevention for patients and parents/caregivers;
4. Describe the latest developments in route of immunization delivery; and
5. Explain how to use Impact SIIS for administering, delivering and tracking immunizations.

ACPE #0129-0000-12-042-L03-P

Ohio Law Update 2012

Kyle W. Parker, MBA, R.Ph., Executive Director, Ohio State Board of Pharmacy

At the completion of this activity, the participant will be able to:

1. Identify recent changes in state and federal laws and regulations which impact the practice of pharmacy;
2. Explain proposed changes in Ohio pharmacy law and rules and the potential effect of these changes on everyday practice; and
3. Apply the recent changes in state and federal laws and regulations to his/her particular practice of pharmacy.

ACPE #0129-0000-12-043-L04-P

Health Care Reform—Creating New Roles for Pharmacists!

Jenelle Sobotka, PharmD, Professor and Endowed Chair, Department of Pharmacy Practice, Ohio Northern University and President of APhA; and Chester Kaczor, R.Ph., PharmD, MBA, Regional Director of Clinical Services Pharmacy Systems, Inc.

At the completion of this activity, the participant will be able to:

1. Outline the national policies adopted with health care reform that support the transitions of care and new patient care practice models;
2. Review the various transitions of care that patients experience with the US health care system and the expected pharmacist roles in these types of practice models;
3. Discuss examples of existing actual practices where these transitions of care models are successful; and
4. Identify the process and action steps needed to implement these models, including development of a comprehensive business plan and proposal from needs assessment to revenue and expense estimation.

ACPE #0129-0000-12-044-L01-P

From the Body to the Eye: Ocular Medication and Common Ocular Side Effects of Systemic Medications

Rachel Dietz, R.Ph., PharmD, Staff Pharmacist, Walgreens

At the completion of this activity, the participant will be able to:

1. Describe the most common ocular medications on the market;
2. Recognize systemic medications from a detailed patient history that cause major side effects on the eye;
3. Identify the common side effects that go along with ocular medications;

4. Exhibit knowledge of information relative to the side effects that occur from systemic medication use; and
5. Discuss strategies for proper patient use of ocular medication and how to increase patient compliance.

ACPE #0129-0000-12-045-L01-P

Aspects and Management of Acute Injury Pain

Mary C. Borovicka, PharmD, BCPS, BCPP; Associate Professor, UT College of Pharmacy and Pharmaceutical Sciences

At the completion of this activity, the participant will be able to:

1. Describe the physiological response to acute injury that results in pain;
2. Select appropriate medication regimens for the treatment of acute pain based on therapeutic goal, side effects encountered and concomitant therapies;
3. Calculate the MED of various opioid regimens; and
4. Identify monitoring parameters and appropriate counseling information for patients receiving opioid therapy for acute pain.

ACPE #0129-0000-12-046-L01-P

Bath Salts and SOAPing

Jon E. Sprague, R.Ph., PhD, ONU Professor of Pharmacology & Dean, College of Pharmacy

At the completion of this activity, the participant will be able to:

1. Identify the most common agents found in bath salts;
2. Identify common street names for bath salts;
3. Discuss the chemical, pharmacological and toxicological similarities of bath salts to other agents of abuse; and
4. Describe the pharmacologic rationale for managing the acute toxicities associated with bath salts.

ACPE #0129-0000-12-047-L04-P

**Mastering Your Message: Crystal Communication of Your Pharmacies Value
(The Three Ways to Attract New Customers)**

*Gabe Trahan, Senior Director of Store Operations and Marketing
National Community Pharmacists Association*

At the completion of this activity, the participant will be able to:

1. Discuss the importance of marketing his/her pharmacy and its professional services.
2. List challenges to communicating his/her message and potential solutions to these challenges.
3. Describe ways to create ads and marketing material by focusing on unique strengths and benefits that his/her pharmacy has to offer.

ACPE #0129-0000-12-048-L04-P

Will a Spoonful of Communication in Pharmacy Practices Help the Medicine Go Down?

Sharon Massen, CPhT, PhD, Professor, Franklin University; Consultant, Massen & Associates

At the completion of this activity, the participant will be able to:

1. Recognize communication problems that may increase conflict;
2. Explain ways to work cooperatively with pharmacy staff, patients, and others who impact customer service and efficient operation of the pharmacy; and
3. Identify tips for success in managing and evaluating the pharmacy staff.

ACPE #0129-0000-12-049-L04-P

Innovative Pharmacy Business Plan Competition 2012

Finalist teams and panel of judges TBA

At the completion of this activity, the participant will be able to:

1. Identify essential components of a business plan, including mission statement, description of business, loan request, marketing plan and financial reports;
2. Recognize the importance of effective visual aids and nonverbal communication during presentation of a business plan; and
3. Explain how enthusiasm, professionalism and completeness can impact the effectiveness of a business plan presentation.

ACPE #0129-0000-12-050-L01-P

Update on Chronic Heart Failure

Rebecca Gryka, PharmD, PhD, Associate Professor and Chair of Pharmaceutical Sciences

Cedarville University School of Pharmacy

At the completion of this activity, the participant will be able to:

1. Describe the common etiologies associated with chronic heart failure (CHF);
2. Discuss the pathophysiology associated with CHF;
3. Outline the typical symptoms seen in a patient presenting with CHF;
4. Discuss the classes of drugs used in the treatment of CHF, outlining their accepted mechanism of action in this disease state; and
5. Outline the approach to treatment of a patient presenting with CHF according to the current ACC/AHA guidelines.

ACPE #0129-0000-12-051-L04-P

Meeting the Medication Needs of Underserved Communities through the 340B Drug Pricing Program

Todd D. Sorensen, PharmD, Consultant

The HRSA Pharmacy Services Support Center at APhA

At the completion of this activity, the participant will be able to:

1. Describe the history and intent of the 340B program;
2. Define opportunities for partnerships between federally-qualified entities and community pharmacists;
3. Outline program design elements for successful application of the 340B program; and
4. Recognize key policy issues currently influencing 340B program application.

ACPE #0129-0000-12-052-L01-P

Aspects and Management of Chronic Pain

Mary C. Borovicka, PharmD, BCPS, BCPP

Associate Professor, UT College of Pharmacy and Pharmaceutical Sciences

At the completion of this activity, the participant will be able to:

1. Differentiate the physiological changes that characterize acute and chronic pain;
2. Select appropriate medication regimens for the treatment of chronic pain based on the source of the pain, therapeutic goal, side effects encountered and concomitant therapies;
3. Describe newer dosage forms developed to reduce product misuse;
4. Explain the role of non-pharmacological interventions in the treatment of chronic pain; and
5. Identify monitoring parameters and appropriate counseling information for patients receiving opioid therapy for chronic pain.

ACPE #0129-0000-12-053-L04-P

Leveraging the Press and Social Media to the Pharmacist's Advantage

*Steve Burson, R.Ph., OPA President, Managed Care Sales Coordinator, The Kroger Co.;
Writer/Producer, Kroger Television Network; and Antonio Ciaccia, OPA Director of Marketing & Public
Affairs*

At the completion of this activity, the participant will be able to:

1. Identify five basic concepts for media interviews;
2. Describe five response techniques for answering media questions;
3. Identify and use six major social media platforms; and
4. Outline a social media strategy for their personal and professional lives.

ACPE #0129-0000-12-054-L05-P

Quality Improvement – A Way to Enhance Patient Safety

Tara M. Modisett, Executive Director, Alliance for Patient Medication Safety

At the completion of this activity, the participant will be able to:

1. Differentiate between types of quality-related events (QRE) – incidents that reach the patient, near misses, and unsafe conditions;
2. Recognize the benefits and challenges of e-prescribing technology;
3. Define Patient Safety Organization (PSO);
4. Define elements of a Continuous Quality Improvement (CQI) program; and
5. Identify ways to implement a continuous quality improvement processes in his/her pharmacy practice.

ACPE #0129-0000-12-055-L01-P

Interventions in Heart Failure: A Pharmacist's Impact

*Jodie Fink, PharmD, BCPS, Heart Failure/Transplantation Clinical Specialist
Cleveland Clinic*

At the completion of this activity, the participant will be able to:

1. Describe the purpose and use of commonly administered heart failure medications;
2. Explain the monitoring necessary for the commonly administered heart failure medications; and
3. Discuss common interventions pharmacists may make to improve the outcomes of heart failure patients.

ACPE #0129-0000-12-056-L01-P

New Drug Update 2012

*Karen L. Kier, Ph.D., M.Sc., R.Ph., Director of Assessment and Professor of Clinical Pharmacy Practice
Ohio Northern University College of Pharmacy*

At the completion of this activity, the participant will be able to:

1. Describe the pharmacology and therapeutics of the drugs presented that were released to market in the past year;
2. Explain the indications, clinical applications and drug interactions of the drugs presented;
3. Recognize the most common adverse effects and toxicities reported with these medications; and
4. Identify important patient counseling information on these medications.

ACPE #0129-0000-12-057-L04-P

Legislative and Regulatory Update for Compounders: What You Don't Know Can Hurt You

David G. Miller, R.Ph., Executive Vice President and CEO

International Academy of Compounding Pharmacists

At the completion of this activity, the participant will be able to:

1. Compare two ongoing actions by the FDA as they pertain to veterinary and human compounding;
2. Explain the statutory meaning of "FDA approved drug product";
3. Describe how CMS definitions of "covered drug products" affect reimbursement and access to API-based compound preparations;
4. Describe federal agency initiatives to restrict and limit the use of APIs for veterinary compounding;
5. Define "constructive transfer" and the difference between judicial and agency interpretations of its legality; and
6. List three different issues which are being addressed by state agencies and how they affect compounding.

ACPE #0129-0000-12-058-L04-P

Legislative and Regulatory Issues: Impact on Pharmacists

Ernest E. Boyd, PharmD (Hon), CAE and Kelly Vyzral, Lobbyists, Ohio Pharmacists Association

At the completion of this activity, the participant will be able to:

1. Identify important federal pharmacy issues;
2. Discuss the important aspects of pharmacy audit legislation; and
3. Explain the impact that DEA regulations have on the practice of pharmacy.

ACPE #0129-0000-12-059-L01-P

OTC Misuse and Abuse

Timothy R. Ulbrich, PharmD, Director of Pharmacy Resident Education and Assistant Professor of Pharmacy Practice, NEOMED

At the completion of this activity, the participant will be able to:

1. Identify over-the-counter (OTC) medications that are commonly misused and abused;
2. Discuss recent legislative actions related to the misuse and abuse of OTC medications; and
3. Develop strategies that health care providers can use to address OTC misuse and abuse.

ACPE #0129-0000-12-060-L04-P

"iPharmacy": Bringing Your Practice to the 21st Century

Melody Hartzler, R.Ph., PharmD, AE-C; and Dustin Hartzler, Website Developer

At the completion of this activity, the participant will be able to:

1. Demonstrate available medical and pharmacy smart phone and tablet applications available for use in clinical practice;
2. Discuss ways to integrate technology in clinical pharmacy practice including community pharmacy;
3. Identify key components for website development; and
4. Discuss the top five features every website should contain.